

Rochester, NY (Newsworthy.ai) Sunday Feb 25, 2024 @ 5:00 PM Eastern —

<u>Upstate Ketamine</u>, an innovative treatment option for patients suffering from psychiatric disorders and chronic pain, has emerged as a significant breakthrough in depression research. An FDA-approved anesthetic with over 50 years of medical use, ketamine is proving to be a game-changer in restoring pathways in the brain and reestablishing communication among nerve cells.

With a strong safety profile and temporary side effects, <u>ketamine infusion therapy</u> has shown remarkable results in improving both function and mood for over 70% of patients. Its rapid relief of depressive symptoms and chronic pain has paved the way for managing treatment-resistant depression, PTSD, fibromyalgia, and other conditions.

Patients seeking ketamine infusion therapy are required to contact the office and undergo an assessment process to determine their eligibility. Upon scheduling their appointment, patients will complete intake forms and be provided a private room for treatment. During the procedure, a small IV catheter will be inserted into the arm, and the infusion will last approximately 40 minutes.

<u>Ketamine infusion therapy</u> offers a fast and highly effective treatment for depression and chronic pain. It provides hope for those who have not responded to traditional treatments, including individuals struggling with suicidal depression.

Embarking on an unparalleled journey of mental health and pain management, <u>ketamine infusion therapy</u> is revolutionizing the way patients can regain control of their lives. Its potential to transform treatment outcomes and provide relief to those who have been previously resistant to other forms of therapy cannot be overlooked.



This press release is distributed by the <u>Newsworthy.ai<sup>™</sup> Press Release Newswire</u> – News Marketing Platform<sup>™</sup>. Reference URL for this press release is <u>here</u>.